| Prev Close | 26.30 |
| Open | 26.03 |
| Day Low/High | 25.16 / 26.67 |
| 52 Wk Low/High | 21.30 / 79.75 |
| Volume | 505.05K |
Prothena Corp. Plc (PRTA)
26.01
0.29
1.10
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 46.81B |
| Market Cap | 1.15B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers
The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.
With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'
Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.
Playing Biotechs with the House's Money
Here's how to lock in gains on risky small-cap biotechnology stocks.
Where the Money Was Made the Last 5 Years
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Questions on Restaurant Ratings
Markets still down at mid-day but up off the lows coinciding with the close of the European stock markets. Following up on my comments on picking up a few more shares earlier today in United Rentals (URI) on recent weakness. The rental side of the h...
Bought a Few More United Rentals
Markets have fallen since our last update, with the Dow off triple digits as we are two hours into the trading day. Oil is having a nice day, up approximately 3% and approaching $60 a barrel again on WTI. Not surprisingly, energy sector outperformi...
Watch the Dollar and Supply
The weak dollar was the breeze that pushed the market higher.
Backing Away From Biotechs
This sector could see some real damage.
Biotech Stocks at a Crossroad
Own them, or take something off the table?
The Next Biotech Breakout?
As always, I am happy to be standing in for Doug Kass today on the Daily Diary (this Friday from sunny Miami). It looks like it will be an up open to talk about based on early market futures. The euro is heading towards its best week in 18 months, e...
These Stocks Get Benefit of the Doubt
Market backtracks on skepticism over biotechs.
Two Small-Cap Biotechs To Consider
Fibrocell Science and Prothena have several 'shots on goal.'
